Johnson & Johnson’s non-mRNA one had some severe side effect incidents that got it pulled, and showed lower vaccine efficacy versus Pfizer and Moderna in trials before then. AstraZeneca’s vaccine was a somewhat similar story.
A lot of vaccines off older tech had no such issues. Notably, Novavax delivered a well tolerated high efficacy shot with more limited post-shot hangovers. Some research indicated that this was particularly true for folks with autoimmune conditions, some cancers, or MECFS.
Johnson & Johnson’s non-mRNA one had some severe side effect incidents that got it pulled, and showed lower vaccine efficacy versus Pfizer and Moderna in trials before then. AstraZeneca’s vaccine was a somewhat similar story.
A lot of vaccines off older tech had no such issues. Notably, Novavax delivered a well tolerated high efficacy shot with more limited post-shot hangovers. Some research indicated that this was particularly true for folks with autoimmune conditions, some cancers, or MECFS.